Wolverine Asset Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Wolverine Asset Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,700	Closed	-$72.1K	–	1943
2023 Q4	$72.1K	Hold	1,700	–	–	﹤0.01%	1164
2023 Q3	$37.1K	Hold	1,700	–	–	﹤0.01%	1277
2023 Q2	$54K	Hold	1,700	–	–	﹤0.01%	1157
2023 Q1	$41.5K	Hold	1,700	–	–	﹤0.01%	1229
2022 Q4	$53.6K	Buy	+1,700	New	+$48K	﹤0.01%	1376

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Wolverine Asset Management's CERE Position: Q3 2021 in Review

Wolverine Asset Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2021, closing a stake of 12,253 shares — an estimated $313K sold.

Wolverine Asset Management first reported a position in CERE in Q3 2020 and held it in 3 quarters. The position peaked at $313K in Q2 2021. 94 funds tracked by Wall St. Rank hold CERE as of Q3 2021.

Wolverine Asset Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Wolverine Asset Management sold 12,253 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2021, an estimated $313K.
Wolverine Asset Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
Wolverine Asset Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $313K in Q2 2021.
94 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2021.

Based on Wolverine Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.